Back to all studies
🎗️
Phase 1
Oncology
in-person

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced S…

Sponsored by Novartis Pharmaceuticals

Compensation

Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.

Duration

3 months

Location

Nationwide

About this study

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Who can participate

  • • Adults aged 18–99
  • • All genders welcome
  • • Diagnosed with or experiencing advanced hr+/her2- breast cancer
  • • Able to attend in-person clinic visits

What's included

  • • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.

Source: ClinicalTrials.gov record NCT06726148

Ready to Find a Research Study?

Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.